Figure 1.

Kaplan–Meier estimates of overall survival (OS) by 1p/19q status in 170 WHO grade II‐IV gliomas. Vertical bars indicate censored cases. A, Survival for WHO grade III IDH‐mutant glioma. OS for 19q‐loss anaplastic astrocytomas (AA; n = 7), 19q‐intact AA (n = 12), and 1p/19q codeleted anaplastic oligodendrogliomas (AO; n = 23) were plotted. OS of 19q‐loss AA was significantly longer than 19q‐intact AA (P = .001, log–rank test), and was not significantly worse than that of anaplastic oligodendrogliomas (P = .93, log–rank test). B, Survival for WHO grade IV IDH‐wild type glioblastomas (GBM). OS for 19q‐loss GBM (n = 14) and 19q‐intact GBM (n = 74) were compared, but there was no significant difference (P = .4, log–rank test). C, Survival for lower grade glioma of The Cancer Genome Atlas cases by 19q status. WHO grade II and III astrocytomas harboring both IDH mutation and TP53 mutation with 19‐loss (n = 23) and 19q‐intact group (n = 204). WHO grade II and III oligodendrogliomas harboring both IDH mutation and TP53 wild‐type with 1p/19q codeletion (n = 159). D, Survival of lower grade gliomas by 19q status in the combined cases of The Cancer Genome Atlas and our series. When combined, OS for the 19q‐loss group (n = 30) was significantly longer than the 19q‐intact group (n = 226) (P = .015, log–rank test). 1p/19q codeletion group (n = 200) is also shown